Literature DB >> 14746810

Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor.

Daisuke Nanba1, Shigeki Higashiyama.   

Abstract

Heparin-binding EGF-like growth factor (HB-EGF), a member of the EGF family, is synthesized as a membrane-anchored precursor (proHB-EGF) that is cleaved to release a soluble HB-EGF by specific metalloproteases. Proteolytic cleavage of proHB-EGF yields amino- and carboxy-terminal fragments (HB-EGF and HB-EGF-C). Recent studies indicate that the processing of proHB-EGF is strictly regulated and involved in a variety of biological processes and that not only HB-EGF but also HB-EGF-C functions as a signaling molecule. ProHB-EGF generates dual intracellular signaling molecules by its proteolytic cleavage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14746810     DOI: 10.1016/j.cytogfr.2003.10.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  20 in total

1.  miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice.

Authors:  Zhipeng Meng; Xianghui Fu; Xiaosong Chen; Samuel Zeng; Yan Tian; Richard Jove; Rongzhen Xu; Wendong Huang
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 3.  Age-Related Macular Degeneration and Intracrine Biology: An Hypothesis.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2016

4.  Helicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activation.

Authors:  Takashi Joh; Hiromi Kataoka; Satoshi Tanida; Katsushi Watanabe; Tadayuki Ohshima; Makoto Sasaki; Haruhisa Nakao; Hirotaka Ohhara; Shigeki Higashiyama; Makoto Itoh
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

5.  Amino-terminal deletion of heparin-binding epidermal growth factor-like growth factor4-127 stimulates cell proliferation but lacks insulin-like activity.

Authors:  Z Zhou; P A Harding
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

6.  The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells.

Authors:  Aleksandra Glogowska; Janette Pyka; Astrid Kehlen; Marek Los; Paul Perumal; Ekkehard Weber; Sheue-yann Cheng; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

Authors:  Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

8.  Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.

Authors:  Aleksandra Glogowska; Jörg Stetefeld; Ekkehard Weber; Saeid Ghavami; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

9.  Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.

Authors:  Enrico A Duru; Yuyang Fu; Mark G Davies
Journal:  J Surg Res       Date:  2014-07-02       Impact factor: 2.192

10.  Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.

Authors:  Andrew M Bakken; Clinton D Protack; Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  J Vasc Surg       Date:  2009-05       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.